Harnessing phage and ribosome display for antibody optimisation.
Therapeutic antibodies have become a major driving force for the biopharmaceutical industry; therefore, the discovery and development of safe and efficacious antibody leads have become competitive processes. Phage and ribosome display are ideal tools for the generation of such molecules and have already delivered an approved drug as well as a multitude of clinical candidates. Because they are capable of searching billions of antibody variants in tailored combinatorial libraries, they are particularly applicable to potency optimisation. In conjunction with targeted, random or semi-rational mutagenesis strategies, they deliver large panels of potent antibody leads. This review introduces the two technologies, compares them with respect to their use in antibody optimisation and highlights how they can be exploited for the successful and efficient generation of putative drug candidates.
Dufner
Patrick
P
Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB1 6GH, UK.
Jermutus
Lutz
L
Minter
Ralph R
RR
D000906:Antibodies / Q000235:genetics / Q000302:isolation & purification*; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000302:isolation & purification; D000918:Antibody Specificity; D007128:Immunoglobulin Fragments / Q000235:genetics / Q000302:isolation & purification; D009154:Mutation; D019151:Peptide Library; D012270:Ribosomes / Q000378:metabolism*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments; D019151:Peptide Library